Dr. Reddy’s was going to report a loss, according to the message on the “Market Chatter” group, which was posted on July 24 from a mobile phone number that Reuters traced back to Nishant Vass, an auto analyst at ICICI Securities, a leading Indian brokerage. The WhatsApp group had 45 members, mostly traders.
According to a statement issued by the city-based drug maker, its generic version of the injection is available in single-dose, 20 ml flint vials containing 20 mg of clofarabine in 20 ml of solution (1mg/mL).
Dolat Capital is bullish on Dr.Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 3450 in its research report dated October 31, 2017.
Forty-six US state attorneys general will seek to expand a lawsuit alleging price fixing of generic drugs to 18 companies and 15 medicines on Tuesday, including Novartis AG's generic unit Sandoz and India-based Sun Pharmaceutical Industries Ltd.
According to a notification put up by the US Food and Drug Administration, the recall is being made under 'Class-III' classification, which is described as 'a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences'.
Net Sales are expected to increase by 5.6 percent Y-o-Y (up 14.2 percent Q-o-Q) to Rs. 3787.8 crore, according to Kotak.
Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today - Tata Motors, Bajaj Auto, Mahindra and Mahindra (M&M), Ashok Leyland, Smartlink, Dr Reddys Laboratories, Adani Group stocks, PNC Infra, Reliance Communications.
The pharma major Dr Reddys Laboratories (DRL) has launched kidney disease drug Renvela generic in the US market. How big an opportunity can this be for DRL and what does it do to Aurobindo Pharma. In an interview to CNBC-TV18, Amey Chalke of HDFC Securities shared his views and readings on the same.
"With regard to the audit of the company's formulation Srikakulam Plant (SEZ) Unit I, Andhra Pradesh...the company have received an EIR from the USFDA, for the above-referred facility," Dr Reddy's said in a regulatory filing.
Pharma stocks have been on an upward trend. In an interview to CNBC-TV18, Deepak Malik, Pharma Analyst of Edelweiss Securities discussed what is happening in the sector.
Edelweiss is bullish on Dr Reddys Laboratories has recommended buy rating on the stock with a target price of Rs 3500 in its research report dated September 20, 2017.
The company has received EIR from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility at Srikakulam unit II, Dr Reddy's said in a filing to BSE.
Divis Laboratories, Dr Reddy's Laboratories, Aurobindo Pharma, Biocon and Lupin will get astrological support, says Satish Gupta of astrostocktips,
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Adani Ports and Special Economic Zone, National Aluminium Company, Dr Reddy's Laboratories and Gujarat State Petronet Limited and can sell Jet Airways and Mahindra & Mahindra.
Ashwani Gujral of ashwanigujral.com is of the view that Tata Steel a momentum play and recommends holding Bombay dyeing while he feels that NBCC is likley to hit Rs 250.
Mitessh Thakkar of mitesshthakkar.com is of the view that one can sell GSFC, Jet Airways and ACC and buy NIIT Technologies and South Indian Bank.
Ashwani Gujral of ashwanigujral.com is of the view that one can buy Bharti Airtel, Dr Reddy's Labs and Bharat Financial Inclusion and can sell Hero MotoCorp and Reliance Capital.
Sanjiv Bhasin of IIFL has ITC, Infosys, Dr Reddy's Labs and NBCC as the top picks.
VK Sharma, Head - PCG and Capital Market Strategy at HDFC Securities recommends buying Tata Communications, Dr Reddy's Laboratories, Mindtree and Cummins India.
Sudarshan Sukhani of s2analytics.com is of the view that one can buy Piramal Enterprises, L&T Finance Holdings and Indiabulls Real Estate and can sell BHEL and Apollo Hospitals.
Commenting on the development, Aurigene CEO CSN Murthy said: "Together with Curis, we have designed a phase II trial in selected populations of patients of interest in the CA-170 programme to be treated at major cancer centres in India".
"The Regulatory Authority of Germany (Regierung von Oberbayern) concluded an audit of our formulations facility in Duvvada, Visakhapatnam with zero critical and six major observations," Dr Reddy's Labs said in a filing to BSE.
Suboxone sublingual film is indicated for the maintenance of treatment of opioid dependence. The US District Court of Delaware has issued a judgement that proposed generic version of Suboxone sublingual film does not infringe US patents as asserted by Indivior, Dr Reddy's Laboratories said in a filing to BSE.
Dr Reddy's Laboratories (DRL) stars in trade with a 7 percent rally after a US judge ruled that the company does not infringe on three suboxone patents. In an interview to CNBC-TV18, Amey Chalke of HDFC Securities shared his take on the stock.
Qysmia is a combination of phentermine and topiramate extended-release sold in capsule form. The drug is used to manage chronic overweight in adults with obesity symptoms.